Adial said the article also included study results that showed low-dose AD04 did not significantly change certain liver injury biomarkers, including ALT, AST and serum bilirubin. GGT levels, which ...

On April 16, 2024, the United States Patent and Trademark Office issued patent number 11957664 to Adial Pharmaceuticals Inc ...

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead ...

Adial Pharmaceuticals shares were up 78% at $2.01 after the company provided promising clinical results, strong safety profile and high compliance among patients administered AD04, or low-dose ...

GLEN ALLEN, Va., April 22, 2024 (GLOBE NEWSWIRE) --. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage ...

Received $4.3 Million in Gross Proceeds from Warrant Exercises Subsequent to Year-End 2023 GLEN ALLEN, Va., April 02, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW ...

Adial Pharmaceuticals (NASDAQ:ADIL) stock rallied 81% in morning trading Wednesday amid the publication of encouraging data for the company's alcohol use disorder drug AD04. Adial said the article ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...